News Focus
News Focus
Followers 88
Posts 3114
Boards Moderated 0
Alias Born 09/07/2014

Re: Slave1 post# 775262

Friday, 07/11/2025 3:09:11 PM

Friday, July 11, 2025 3:09:11 PM

Post# of 828325
Slave1, I believe your post here answers the questions I had from yesterday that I was going to PM you about. But now that it was brought up by others, I'll explore it a little more here in the open. That question: "Is Merck trying to side-step us by using trials with Roswell Park and Mayo Clinic that seem to mimic what we own?"

Yesterday, among other perplexing comments, you wrote in reference to Mayo/Roswell pooled tumor lysate trials with Merck:

The product in question might not be separate at all (from our DCVax products). It may be the same architecture, the same immune engine, just stripped of its autologous tumor input. Who is behind it has not been named, (NWB?) but the blueprint is unmistakable.



Then you went on to write about the Merck trials:

Several trials sponsored by Roswell Park or Kalinski’s lab have combined dendritic cell vaccines with checkpoint inhibitors like pembrolizumab. These include studies in colorectal cancer, head and neck cancer, and solid tumors, with Merck often providing drug or in-kind support. The protocols are structurally similar to DCVax-Direct, using antigen loaded dendritic cells matured under Kalinski’s patented cytokine conditions. That intellectual property belongs to Roswell Park and remains exclusively licensed to Northwest Biotherapeutics.



Then today you said unequivocally:

The company (NWBO) holds the rights to a specific method combining pooled tumor lysate with autologous dendritic cells to induce immune responses against solid tumors. That is the approach Mayo studied, Mill Creek manufactured, and NWBO controls under its license.

Taken together, the data, funding, and regulatory position suggest that while development occurred across institutions, the underlying platform method remains within NWBO’s IP framework.



So, my final question is: If it's true that Merck is testing it's Keytruda with NWBO's in-licenced DC products from Roswell, are they plotting to get ahead of us or planning to partner with us? I'm not actually asking you to make a wild guess, so much as an educated one, based on the facts.
Thanks, Slave1! Have a great weekend!
Bullish
Bullish
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NWBO News